The FDA's Oncologic Drug Advisory Committee will look at reducing the central review audit burden as a way to streamline cancer trials.

The FDA's Dermatologic and Ophthalmic Drug Advisory Committee gave unanimous support for Genentech Inc.'s Lucentis 0.3 mg (ranibizumab injection) as a treatment for diabetic macular edema (DME) and for ThromboGenics Inc.'s ocriplasmin to treat symptomatic vitreomacular adhesions (VMAs).

The Federal Circuit Court revisits the Myriad breast cancer gene claims.